Abstract
CD4+ Foxp3+ regulatory T cell (Treg) therapy in organ transplantation is being examined in phase I/II studies. However, Treg fate after infusion remains unknown, and concerns persist that they may convert into effector cells. We recently described a novel method for generating alloantigen-reactive Tregs using the phosphodiesterase 3b (PDE3b) inhibitor cilostamide (cilos Tregs). We hypothesized that cilos Tregs would exhibit superior phenotypic and functional stability compared with transforming growth factor β-generated Tregs (TGFβ Tregs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
